EHL products, which feature a recombinant FVIII Fc fusion protein (rFVIIIFc), have shown low annualized bleeding rates (ABR) in patients with severe hemophilia A undergoing individualized prophylactic treatment [12,13]. Here, F8 is linked to hemophilia A.